dr holst glp 1 Jens Juul of the Novo Nordisk Foundation Center for Basic Metabolic Research and the University of Copenhagen was awarded the 2025 Breakthrough Prize in Life Sciences for his discovery and characterization Researcher receives prize for huge

Dual- and multi-receptor agonists may be a novel drug class to treat obesity and type 2 diabetes mellitus with high efficacy.

A five-year experiment reportedly aims to expand access to blockbuster GLP1 drugs for obesity, something advocates have sought for years

#GuaPHL | Ojo con los GLP-1

Learn about the differences between these treatments, how each works, and what else to consider.

Sarcopenia is an age-related syndrome characterized by a progressive and extensive decline in skeletal muscle mass and function, leading to serious impairment of the quality of life and poor health prognosis in older adults

Free online community helps people using or considering GLP-1 therapies connect, share experiences, ask questions, and find support from others navigating...